Transferring a Medical Technology Factory from Hamburg to the Netherlands

Executive Summary

Manufacturing transfer of a regulated medical technology factory from Hamburg to the Netherlands. The Program was connected to a €500M product portfolio value, a €10M project budget, and the coordination of a 300-member cross-functional team. The work covered Program governance, site readiness, factory setup, machinery transfer, process transfer, knowledge transfer, workforce ramp-up, regulatory readiness, quality control, and COVID-era risk management. The Program was completed on time and within budget, while maintaining operational continuity and production readiness.

Challenge

The organization needed to relocate a regulated manufacturing operation across countries without losing control of quality, compliance, schedule, budget, or supply continuity. The Program involved transferring not only equipment, but also processes, tools, production knowledge, trained capability, and operational responsibility. The core challenges included: relocation of a regulated medical technology manufacturing operation coordination of a 300-member cross-functional team governance of a €10M project budget continuity protection for a €500M product portfolio value machinery, process, tool, and documentation transfer hiring, onboarding, and training of new employees regulatory readiness and quality control during the transfer COVID-19 restrictions affecting travel, collaboration, and execution maintaining production continuity while building the new manufacturing setup The Program required disciplined execution control because every delay or quality issue could affect supply continuity, compliance readiness, and business performance.

Role & Scope

As Program Manager, the role covered Program governance, cross-functional team leadership, budget control, site readiness, facility coordination, transfer planning, risk management, stakeholder alignment, regulatory readiness, and operational handover. The Program involved engineering, operations, HR, finance, logistics, quality, regulatory, facility, production, and leadership stakeholders. Responsibilities included chairing the Program governance rhythm, managing decisions and escalations, coordinating workstreams, tracking readiness, and driving execution toward a controlled factory transfer.

Approach

The Program was structured around clear workstreams, milestones, readiness criteria, risk controls, and escalation paths. The transfer plan connected site readiness, facility setup, machinery movement, process documentation, knowledge transfer, workforce ramp-up, quality systems, and production continuity. The approach included: Program charter and governance setup stakeholder alignment across sites and functions budget and milestone control site readiness and factory setup coordination machinery and equipment transfer planning installation and commissioning coordination process mapping and transfer documentation knowledge transfer from experienced teams to the new workforce employee hiring, onboarding, and training support regulatory approval and quality readiness tracking COVID-19 health, safety, and collaboration measures executive reporting and escalation management Particular focus was placed on maintaining control during the COVID-19 period. Remote collaboration, adapted governance, health and safety protocols, and risk mitigation measures were used to maintain Program momentum despite operational constraints.

Key Contributions

• Established the Program structure for the cross-border transfer of a regulated medical technology manufacturing operation.
• Led a 300-member cross-functional team across engineering, operations, HR, finance, logistics, quality, regulatory, facility, production, and leadership functions.
• Governed a €10M project budget connected to a €500M product portfolio value.
• Coordinated site readiness, factory setup, machinery transfer, installation, commissioning, and production preparation.
• Structured process mapping, documentation, and knowledge transfer to support operational continuity.
• Managed workforce ramp-up through hiring, onboarding, training, and transition support.
• Integrated regulatory readiness and quality control into the transfer plan.
• Maintained execution control during COVID-19 through adapted governance, remote collaboration, and risk mitigation measures.

Impact

• €500M product portfolio value connected to the transfer
• €10M project budget governed
• 300-member cross-functional team led and coordinated
• 100% on-time completion
• Completed within budget
• The Program established operational manufacturing capability in the Netherlands while protecting continuity for a high-value product portfolio. It created a controlled transition from the previous manufacturing environment into the new setup, with transferred equipment, documented processes, trained employees, and maintained quality and regulatory readiness.

Capabilities Demonstrated

• Program leadership
• Manufacturing transfer
• Factory relocation
• Regulated medical technology manufacturing
• Cross-functional team leadership
• Budget and milestone governance
• Operational readiness
• Process and knowledge transfer
• Quality and regulatory readiness
• COVID-era risk management